Australia
· Delayed Price · Currency is AUD Botanix Pharmaceuticals Statistics
Total Valuation
Botanix Pharmaceuticals has a market cap or net worth of AUD 572.50 million. The enterprise value is 493.19 million.
| Market Cap | 572.50M |
| Enterprise Value | 493.19M |
Important Dates
The next estimated earnings date is Tuesday, November 26, 2024.
| Earnings Date | Nov 26, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Botanix Pharmaceuticals has 1.82 billion shares outstanding. The number of shares has increased by 30.12% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.82B |
| Shares Change (YoY) | +30.12% |
| Shares Change (QoQ) | +8.73% |
| Owned by Insiders (%) | 9.08% |
| Owned by Institutions (%) | 11.08% |
| Float | 1.59B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 228.59 |
| PB Ratio | 5.24 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -35.56 |
| EV / Sales | 238.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -59.85 |
Financial Position
The company has a current ratio of 22.21
| Current Ratio | 22.21 |
| Quick Ratio | 21.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,312.69 |
Financial Efficiency
Return on equity (ROE) is -21.07% and return on invested capital (ROIC) is -13.28%.
| Return on Equity (ROE) | -21.07% |
| Return on Assets (ROA) | -12.74% |
| Return on Capital (ROIC) | -13.28% |
| Revenue Per Employee | 188,135 |
| Profits Per Employee | -1.26M |
| Employee Count | 11 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.68 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.00% in the last 52 weeks. The beta is 1.71, so Botanix Pharmaceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | +95.00% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.31 |
| Relative Strength Index (RSI) | 38.55 |
| Average Volume (20 Days) | 5,328,639 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Botanix Pharmaceuticals had revenue of AUD 2.07 million and -13.87 million in losses. Loss per share was -0.01.
| Revenue | 2.07M |
| Gross Profit | -1.58M |
| Operating Income | -13.99M |
| Pretax Income | -13.87M |
| Net Income | -13.87M |
| EBITDA | -13.92M |
| EBIT | -13.99M |
| Loss Per Share | -0.01 |
Balance Sheet
| Cash & Cash Equivalents | 79.31M |
| Total Debt | n/a |
| Net Cash | 79.31M |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 108.73M |
| Book Value Per Share | 0.06 |
| Working Capital | 79.17M |
Cash Flow
In the last 12 months, operating cash flow was -8.13 million and capital expenditures -112,700, giving a free cash flow of -8.24 million.
| Operating Cash Flow | -8.13M |
| Capital Expenditures | -112,700 |
| Free Cash Flow | -8.24M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | -76.48% |
| Operating Margin | -676.11% |
| Pretax Margin | -670.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -398.17% |
Dividends & Yields
Botanix Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.12% |
| Shareholder Yield | -30.12% |
| Earnings Yield | -2.93% |
| FCF Yield | -1.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Botanix Pharmaceuticals has an Altman Z-Score of 45.72.
| Altman Z-Score | 45.72 |
| Piotroski F-Score | n/a |